Human α4β2 Nicotinic Acetylcholine Receptor as a Novel Target of Oligomeric α-Synuclein

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Liu, Qiang ^a   Emadi, Sharareh ^b   Shen, Jian Xin ^c   Sierks, Michael R ^b   Wu, Jie ^a,c,d  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b Arizona State University   (United States)

^c SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; NICOTINIC RECEPTOR ALPHA4BETA2;

ARTICLE; ATOMIC FORCE MICROSCOPY; CHOLINERGIC SYSTEM; GEL PERMEATION CHROMATOGRAPHY; GENETIC TRANSFECTION; HUMAN; INTERNALIZATION; PATCH CLAMP; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION;

ALPHA-SYNUCLEIN; CHROMATOGRAPHY, GEL; ENDOCYTOSIS; HUMANS; ION CHANNEL GATING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; RECEPTORS, NICOTINIC;

EID: 84874267789     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055886     Document Type: Article

References (58)

1. Brown RE, McKenna JT, Winston S, Basheer R, Yanagawa Y, et al. (2008) Characterization of GABAergic neurons in rapid-eye-movement sleep controlling regions of the brainstem reticular formation in GAD67-green fluorescent protein knock-in mice. Eur J Neurosci 27: 352-363.
2. Son JH, Winzer-Serhan UH, (2008) Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs in rat hippocampal GABAergic interneurons. J Comp Neurol 511: 286-299.
3. Tamamaki N, Yanagawa Y, Tomioka R, Miyazaki J, Obata K, et al. (2003) Green fluorescent protein expression and colocalization with calretinin, parvalbumin, and somatostatin in the GAD67-GFP knock-in mouse. J Comp Neurol 467: 60-79.
4. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, et al. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152: 879-884.
5. Liu Q, Wu J, (2006) Neuronal nicotinic acetylcholine receptors serve as sensitive targets that mediate beta-amyloid neurotoxicity. Acta Pharmacol Sin 27: 1277-1286.
6. Allison DW, Wilcox RS, Ellefsen KL, Askew CE, Hansen DM, et al. (2011) Mefloquine effects on ventral tegmental area dopamine and GABA neuron inhibition: a physiologic role for connexin-36 GAP junctions. Synapse 65: 804-813.
7. Texido L, Ros E, Martin-Satue M, Lopez S, Aleu J, et al. (2005) Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity. Br J Pharmacol 145: 672-678.
8. Aracava Y, Pereira EF, Maelicke A, Albuquerque EX, (2005) Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther 312: 1195-1205.
9. Fayuk D, Yakel JL, (2004) Regulation of nicotinic acetylcholine receptor channel function by acetylcholinesterase inhibitors in rat hippocampal CA1 interneurons. Mol Pharmacol 66: 658-666.
10. Emadi S, Kasturirangan S, Wang MS, Schulz P, Sierks MR, (2009) Detecting morphologically distinct oligomeric forms of alpha-synuclein. J Biol Chem 284: 11048-11058.
11. Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, et al. (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305: 1024-1036.
12. Patel MN, Yim GK, Isom GE, (1993) N-methyl-D-aspartate receptors mediate cyanide-induced cytotoxicity in hippocampal cultures. Neurotoxicology 14: 35-40.
13. Frandsen A, Drejer J, Schousboe A, (1989) Direct evidence that excitotoxicity in cultured neurons is mediated via N-methyl-D-aspartate (NMDA) as well as non-NMDA receptors. J Neurochem 53: 297-299.
14. McClure-Begley TD, King NM, Collins AC, Stitzel JA, Wehner JM, et al. (2009) Acetylcholine-stimulated [3H]GABA release from mouse brain synaptosomes is modulated by alpha4beta2 and alpha4alpha5beta2 nicotinic receptor subtypes. Mol Pharmacol 75: 918-926.
15. Buhler AV, Dunwiddie TV, (2002) alpha7 nicotinic acetylcholine receptors on GABAergic interneurons evoke dendritic and somatic inhibition of hippocampal neurons. J Neurophysiol 87: 548-557.
16. Ji D, Lape R, Dani JA, (2001) Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron 31: 131-141.
17. Alkondon M, Albuquerque EX, (2001) Nicotinic acetylcholine receptor alpha7 and alpha4beta2 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus. J Neurophysiol 86: 3043-3055.
18. Ji D, Dani JA, (2000) Inhibition and disinhibition of pyramidal neurons by activation of nicotinic receptors on hippocampal interneurons. J Neurophysiol 83: 2682-2690.
19. Chen D, Patrick JW, (1997) The alpha-bungarotoxin-binding nicotinic acetylcholine receptor from rat brain contains only the alpha7 subunit. J Biol Chem 272: 24024-24029.
20. Murray TA, Bertrand D, Papke RL, George AA, Pantoja R, et al. (2012) alpha7beta2 nicotinic acetylcholine receptors assemble, function, and are activated primarily via their alpha7-alpha7 interfaces. Mol Pharmacol 81: 175-188.
21. Velez-Fort M, Audinat E, Angulo MC, (2009) Functional alpha 7-containing nicotinic receptors of NG2-expressing cells in the hippocampus. Glia 57: 1104-1114.
22. Louis ED, Benito-Leon J, Bermejo-Pareja F, (2008) Population-based prospective study of cigarette smoking and risk of incident essential tremor. Neurology 70: 1682-1687.
23. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J, (2011) Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 26 (Suppl 1): S1-58.
24. Chen H, Huang X, Guo X, Mailman RB, Park Y, et al. (2010) Smoking duration, intensity, and risk of Parkinson disease. Neurology 74: 878-884.
25. Kiyohara C, Kusuhara S, (2011) Cigarette smoking and Parkinson's disease: a meta-analysis. Fukuoka Igaku Zasshi 102: 254-265.
26. Sharma G, Vijayaraghavan S, (2001) Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores. Proc Natl Acad Sci U S A 98: 4148-4153.
27. Kawamata J, Suzuki S, Shimohama S, (2012) alpha7 nicotinic acetylcholine receptor mediated neuroprotection in Parkinson's disease. Curr Drug Targets 13: 623-630.
28. Jeyarasasingam G, Tompkins L, Quik M, (2002) Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture. Neuroscience 109: 275-285.
29. Takeuchi H, Yanagida T, Inden M, Takata K, Kitamura Y, et al. (2009) Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models. J Neurosci Res 87: 576-585.
30. Lester DB, Rogers TD, Blaha CD, (2010) Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16: 137-162.
31. Guan ZZ, Nordberg A, Mousavi M, Rinne JO, Hellstrom-Lindahl E, (2002) Selective changes in the levels of nicotinic acetylcholine receptor protein and of corresponding mRNA species in the brains of patients with Parkinson's disease. Brain Res 956: 358-366.
32. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L, (2011) Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol 10: 1015-1025.
33. Quik M, Wonnacott S, (2011) alpha6beta2* and alpha4beta2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol Rev 63: 938-966.
34. Eaton JB, Peng JH, Schroeder KM, George AA, Fryer JD, et al. (2003) Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Mol Pharmacol 64: 1283-1294.
35. Peng JH, Lucero L, Fryer J, Herl J, Leonard SS, et al. (1999) Inducible, heterologous expression of human alpha7-nicotinic acetylcholine receptors in a native nicotinic receptor-null human clonal line. Brain Res 825: 172-179.
36. Puchacz E, Buisson B, Bertrand D, Lukas RJ, (1994) Functional expression of nicotinic acetylcholine receptors containing rat alpha 7 subunits in human SH-SY5Y neuroblastoma cells. FEBS Lett 354: 155-159.
37. Lukas RJ, Norman SA, Lucero L, (1993) Characterization of Nicotinic Acetylcholine Receptors Expressed by Cells of the SH-SY5Y Human Neuroblastoma Clonal Line. Mol Cell Neurosci 4: 1-12.
38. Bencherif M, Lukas RJ, (1993) Cytochalasin modulation of nicotinic cholinergic receptor expression and muscarinic receptor function in human TE671/RD cells: a possible functional role of the cytoskeleton. J Neurochem 61: 852-864.
39. He P, Liu Q, Wu J, Shen Y, (2012) Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons. FASEB J 26: 334-345.
40. Liu Q, Huang Y, Xue F, Simard A, DeChon J, et al. (2009) A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 29: 918-929.
41. Wu J, Liu Q, Yu K, Hu J, Kuo YP, et al. (2006) Roles of nicotinic acetylcholine receptor beta subunits in function of human alpha4-containing nicotinic receptors. J Physiol 576: 103-118.
42. Volles MJ, Lansbury PT Jr, (2007) Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol 366: 1510-1522.
43. Hall S, Ohrfelt A, Constantinescu R, Andreasson U, Surova Y, et al. (2012) Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders. Arch Neurol: 1-8.
44. Luscher C, Xia H, Beattie EC, Carroll RC, von Zastrow M, et al. (1999) Role of AMPA receptor cycling in synaptic transmission and plasticity. Neuron 24: 649-658.
45. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, et al. (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 251: 205-208.
46. Conway KA, Lee SJ, Rochet JC, Ding TT, Harper JD, et al. (2000) Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Ann N Y Acad Sci 920: 42-45.
47. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, et al. (1999) alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 274: 19509-19512.
48. Ding TT, Lee SJ, Rochet JC, Lansbury PT Jr, (2002) Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 41: 10209-10217.
49. Volles MJ, Lansbury PT Jr, (2003) Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42: 7871-7878.
50. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, et al. (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40: 7812-7819.
51. Everitt BJ, Robbins TW, (1997) Central cholinergic systems and cognition. Annu Rev Psychol 48: 649-684.
52. Lukas RJ, Changeux JP, Le Novere N, Albuquerque EX, Balfour DJ, et al. (1999) International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 51: 397-401.
53. Lindstrom J, (1996) Neuronal nicotinic acetylcholine receptors. Ion Channels 4: 377-450.
54. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ, (1992) A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 41: 31-37.
55. Whiting P, Lindstrom J, (1987) Purification and characterization of a nicotinic acetylcholine receptor from rat brain. Proc Natl Acad Sci U S A 84: 595-599.
56. Gotti C, Moretti M, Bohr I, Ziabreva I, Vailati S, et al. (2006) Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol Dis 23: 481-489.
57. Martin-Ruiz CM, Piggott M, Gotti C, Lindstrom J, Mendelow AD, et al. (2000) Alpha and beta nicotinic acetylcholine receptors subunits and synaptophysin in putamen from Parkinson's disease. Neuropharmacology 39: 2830-2839.
58. Perry EK, Perry RH, Smith CJ, Purohit D, Bonham J, et al. (1986) Cholinergic receptors in cognitive disorders. Can J Neurol Sci 13: 521-527.